Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

2.

Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.

Yamauchi T, Matsuda Y, Tasaki T, Negoro E, Ikegaya S, Takagi K, Yoshida A, Urasaki Y, Ueda T.

Cancer Sci. 2012 Sep;103(9):1722-9. doi: 10.1111/j.1349-7006.2012.02343.x. Epub 2012 Jul 11.

3.

In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.

Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ, Knapp WH.

Eur J Nucl Med Mol Imaging. 2010 May;37(5):851-61. doi: 10.1007/s00259-009-1356-x. Epub 2010 Jan 27.

PMID:
20107790
4.

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB.

PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.

5.
6.

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML.

Blood. 2003 Aug 15;102(4):1466-73. Epub 2003 Apr 10.

7.

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R.

Leukemia. 2002 May;16(5):813-9.

8.

The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.

Ascione A, Cianfriglia M, Dupuis ML, Mallano A, Sau A, Pellizzari Tregno F, Pezzola S, Caccuri AM.

Cancer Chemother Pharmacol. 2009 Jul;64(2):419-24. doi: 10.1007/s00280-009-0960-6. Epub 2009 Mar 15.

PMID:
19288261
9.

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R.

Leukemia. 2000 Aug;14(8):1436-43.

PMID:
10942240
10.

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.

Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR.

Blood. 2007 May 15;109(10):4168-70. Epub 2007 Jan 16.

11.

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L.

Exp Hematol. 2009 Jun;37(6):755-66. doi: 10.1016/j.exphem.2009.03.002.

PMID:
19463775
12.

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W.

Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5.

PMID:
19262596
13.

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.

Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID.

Blood. 2005 Feb 1;105(3):1295-302. Epub 2004 Sep 28.

14.

The role of gemtuzumab ozogamicin in acute leukaemia therapy.

Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM.

Br J Haematol. 2006 Feb;132(4):398-409. Review.

PMID:
16412015
15.
16.

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.

Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID.

Blood. 2001 Aug 15;98(4):988-94.

17.

Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.

Rutella S, Bonanno G, Procoli A, Mariotti A, Lucia MB, Contemi AM, Cauda R, Fianchi L, Scambia G, Pagano L, Leone G.

Exp Hematol. 2006 Jan;34(1):54-65.

PMID:
16413391
18.
19.

The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.

Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y.

Anticancer Res. 2009 Nov;29(11):4589-96.

20.

Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.

Krauth MT, Böhm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, Sotlar K, Valent P.

Exp Hematol. 2007 Jan;35(1):108-16.

PMID:
17198879

Supplemental Content

Support Center